Eurofins Announces Its Intention to Issue New Hybrid Bonds to Refinance Part of Its Existing Hybrid Bonds

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:

Eurofins Scientific (EUFI.PA, rated Baa3 by Moody’s and BBB- by Fitch) (Paris:ERF), a global leader in bioanalytical testing, announces today:

• its intention to issue a new Euro-denominated hybrid bond for an amount of €400m (“New Hybrid Bond”)

and

• the launch of tender offer (the “Tender Offer”) to repurchase its €400m 3.250% hybrid bond (ISIN: XS1716945586) issued on 13 November 2017 with a first call date of 13 November 2025 (“2025 Hybrid Bond”)

The Tender Offer is subject to the success of the issuance of the New Hybrid Bond. Any 2025 Hybrid Bond validly tendered will be accepted for repurchase.

Results of the Tender Offer are expected to be announced on 03 April 2025 (subject to change as a result of any extension, withdrawal, termination or amendment of the Tender Offer).

The purpose of the Tender Offer and the planned issuance of the New Hybrid Bond is to proactively manage the refinancing of Eurofins' outstanding hybrid instruments and to increase the average life of its financing instruments.

Notes to Editors:

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins Scientific S.E. network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With ca. 63,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.

The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions.

Shares in Eurofins Scientific S.E. are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins Scientific S.E. through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific S.E.’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific S.E. disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.